Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Urinary Bladder Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Triple Negative Breast Neoplasms 2Carcinoma, Transitional Cell 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 28Paclitaxel 21Cisplatin 9Topotecan 8Docetaxel 7Taxes 6Oxaliplatin 5Gemcitabine 5Chemotherapy, Adjuvant 5Bevacizumab 5aldesleukin 4Interleukin-12 Subunit p35 4Erlotinib Hydrochloride 4Drug Therapy 4Interleukin-12 3Immunohistochemistry 3Imatinib Mesylate 3Gene Expression Profiling 3Flow Cytometry 3Filgrastim 3Cyclophosphamide 3Amplified Fragment Length Polymorphism Analysis 3trioctyl phosphine oxide 2temsirolimus 2sargramostim 2oregovomab 2ixabepilone 2irofulven 2cediranib 2carboxyamido-triazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Ovarian Epithelial × eribulin × Clear all
NCT00334893 2017-11-29

Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Completed
74 enrolled 7 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡